Equities

Neumora Therapeutics Inc

NMRA:NSQ

Neumora Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.78
  • Today's Change-0.535 / -4.73%
  • Shares traded1.36m
  • 1 Year change-9.91%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments454372409
Total Receivables, Net0.940.920.20
Total Inventory------
Prepaid expenses23156.03
Other current assets, total00.050.13
Total current assets478388416
Property, plant & equipment, net6.86114.04
Goodwill, net------
Intangibles, net------
Long term investments9.85240
Note receivable - long term------
Other long term assets00.000.20
Total assets496426429
LIABILITIES
Accounts payable0.347.151.64
Accrued expenses251520
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.141.641.49
Total current liabilities252423
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total2.015.701.38
Total liabilities272925
SHAREHOLDERS EQUITY
Common stock0.020.000.00
Additional paid-in capital1,1732111
Retained earnings (accumulated deficit)(703)(468)(337)
Treasury stock - common------
Unrealized gain (loss)(0.08)(0.77)0
Other equity, total------
Total equity469397405
Total liabilities & shareholders' equity496426429
Total common shares outstanding159152152
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.